Pharmaceuticals

Rising Autoimmune Disease Cases Acting as a Major Driver for the Autoimmune Hemolytic Anemia Treatment Market

March 18, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Autoimmune Hemolytic Anemia Treatment Market By The End Of 2030?

The autoimmune hemolytic anemia treatment market has seen significant expansion in recent years. It is projected to increase from $1.4 billion in 2025 to $1.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.6%. The historical surge can be ascribed to autoimmune disorder prevalence, a rise in anemia diagnosis, corticosteroid usage, hospital hematology services, and greater blood disorder awareness.

The autoimmune hemolytic anemia treatment market size is anticipated to see robust expansion in the upcoming years. It is projected to reach $2.11 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.6%. This predicted growth during the forecast period is primarily driven by factors such as the advancement of targeted immunotherapy, the development of personalized treatment protocols, the availability of early diagnostic tools, improved long-term disease management approaches, and continued biologic therapy research. Key trends in the forecast period are expected to include an increased reliance on corticosteroid therapy, a growing adoption of immunosuppressive agents, the broadening of second-line treatment options, enhanced early diagnosis and monitoring efforts, and a strong focus on minimizing complications related to treatment.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24161&type=smp

What Primary Drivers Are Shaping The Development Of The Autoimmune Hemolytic Anemia Treatment Market?

The increasing incidence of autoimmune conditions is anticipated to fuel the expansion of the autoimmune hemolytic anemia treatment market in the future. Autoimmune disorders are defined as conditions where the immune system incorrectly targets the body’s own tissues, leading to inflammation and damage. This growing prevalence is primarily influenced by genetic factors that heighten an individual’s vulnerability to such conditions. Managing the complications of autoimmune diseases heavily relies on autoimmune hemolytic anemia treatment, which works by targeting and diminishing the destruction of red blood cells by the immune system. For example, in May 2023, the National Institute for Health and Care Research (NIHR), a UK organization that funds, supports, and conducts health and care research to enhance public health and well-being, reported specific findings. A study involving 22 million people revealed that autoimmune disorders now affect roughly one in ten individuals, with 19 types of autoimmune diseases impacting about 10% of the population, specifically 13% of women and 7% of men. Consequently, the rising occurrence of autoimmune diseases will stimulate the growth of the autoimmune hemolytic anemia treatment market.

Which Segment Classifications Shape The Autoimmune Hemolytic Anemia Treatment Market?

The autoimmune hemolytic anemia treatment market covered in this report is segmented –

1) By Type: Warm Autoimmune Hemolytic Anemia, Cold Autoimmune Hemolytic Anemia, Other Types

2) By Drug Class: Corticosteroids, Immunosuppressive Agents, Other Drug Classes

3) By Route Of Administration: Injectable, Oral, Other Route Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Warm Autoimmune Hemolytic Anemia: Primary Warm Autoimmune Hemolytic Anemia, Secondary Warm Autoimmune Hemolytic Anemia

2) By Cold Autoimmune Hemolytic Anemia: Primary Cold Agglutinin Disease (CAD), Secondary Cold Autoimmune Hemolytic Anemia

3) By Other Types: Mixed-Type Autoimmune Hemolytic Anemia, Paroxysmal Cold Hemoglobinuria (PCH), Drug-Induced Autoimmune Hemolytic Anemia

How Are Trends Impacting The Autoimmune Hemolytic Anemia Treatment Market?

Leading companies within the autoimmune hemolytic anemia (AIHA) treatment market are concentrating on developing advanced targeted immunotherapies to enhance disease control, reduce hemolysis, and provide safer long-term management solutions for patients. These targeted immunotherapies aim to modulate specific immune pathways responsible for the destruction of red blood cells, thus addressing the underlying autoimmune mechanism rather than solely managing symptoms. For instance, in June 2025, HUTCHMED, a China-based biopharmaceutical company, initiated its Phase II/III registration trial (ESLIM-02) to evaluate sovleplenib, a selective Syk inhibitor, for the treatment of warm autoimmune hemolytic anemia (wAIHA). This trial is designed to assess the drug’s capability to inhibit immune-mediated hemolysis, improve hemoglobin levels, and offer a novel therapeutic choice for patients who have limited alternative treatments.

Which Companies Are Expanding Their Footprint In The Autoimmune Hemolytic Anemia Treatment Market?

Major companies operating in the autoimmune hemolytic anemia treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., Hutchison China MediTech Limited, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Kezar Life Sciences Inc.

Read the full autoimmune hemolytic anemia treatment market report here:

https://www.thebusinessresearchcompany.com/report/autoimmune-hemolytic-anemia-treatment-global-market-report

How Does The Autoimmune Hemolytic Anemia Treatment Market Perform Across Major Global Regions?

North America was the largest region in the autoimmune hemolytic anemia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune hemolytic anemia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Autoimmune Hemolytic Anemia Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24161&type=smp

Browse Through More Reports Similar to the Global Autoimmune Hemolytic Anemia Treatment Market 2026, By The Business Research Company

Autoimmune Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795